Opinion|Videos|September 5, 2024
Advanced Treatment Options for RA: Exploring the Data
Panelists discuss advanced treatment options for rheumatoid arthritis, focusing on the SELECT-COMPARE trial's head-to-head data of upadacitinib versus adalimumab, the use of upadacitinib in active RA refractory to biologics (SELECT-BEYOND trial), and the remission rates of upadacitinib compared to abatacept (SELECT-CHOICE trial).
Advertisement
Episodes in this series
Video content above is prompted by the following:
Let’s discuss data of advanced treatment options for rheumatoid arthritis (RA) that may offer a faster pathway to achieving remission.
- Please discuss the SELECT-COMPARE trial head-to-head data on upadacitinib vs adalimumab.
- Please discuss the use of upadacitinib for active RA refractory to biologic disease-modifying antirheumatic drugs (SELECT-BEYOND trial).
- What are the remission rates seen with upadacitinib vs abatacept (SELECT-CHOICE trial)?
Advertisement
Related to this article
Amplio Pharma now planning a phase 2a study after NovoBioJect raised intracellular active methotrexate levels by 38%.
The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.
August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.
Advertisement
Advertisement
Trending on Rheumatology Live
1
Nipocalimab, Telitacicept, and the Sjögren’s Disease Pipeline
2
Dazodalibep Eases Sjögren’s Dryness via CD40L Blockade: Ghaith Noaiseh, MD
3
Dazodalibep Lowers Sjögren’s Disease Activity: Ghaith Noaiseh, MD
4
INDIGO: Obexelimab Sustains IgG4-RD Flare Control, With John Stone, MD, MPH
5